Ardelyx to Showcase Tenapanor Data at ASN Kidney Week 2026

  • Ardelyx will present three abstracts at ASN Kidney Week 2026, focusing on hyperphosphatemia management.
  • Poster presentations will cover real-world effectiveness of tenapanor, patient perspectives, and morbidity/mortality risks.
  • An Exhibitor Spotlight session will feature an in-depth look at XPHOZAH (tenapanor) on October 23, 2026.
  • XPHOZAH is the only FDA-approved phosphate absorption inhibitor for CKD patients on dialysis.

Ardelyx's presentation at ASN Kidney Week 2026 underscores the growing importance of innovative therapies in managing hyperphosphatemia, a critical condition for CKD patients on dialysis. The focus on real-world evidence and patient perspectives aligns with broader industry trends toward value-based healthcare and patient-centered outcomes. With XPHOZAH as its flagship product, Ardelyx is positioning itself as a key player in the nephrology space, competing against established phosphate binder therapies.

Clinical Validation
How the real-world effectiveness data will impact XPHOZAH's adoption among nephrologists.
Market Differentiation
Whether Ardelyx can position XPHOZAH as a superior alternative to traditional phosphate binders.
Regulatory Dynamics
The pace at which additional indications or label expansions for tenapanor could be pursued.